Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Payables (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Payables for 8 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 39.87% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.3 million, a 39.87% increase, with the full-year FY2024 number at $1.3 million, down 55.8% from a year prior.
  • Payables was $1.3 million for Q3 2025 at Precision Biosciences, up from $1.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $3.0 million in Q4 2023 to a low of $445000.0 in Q1 2021.
  • A 5-year average of $983105.3 and a median of $924000.0 in 2025 define the central range for Payables.
  • Peak YoY movement for Payables: plummeted 74.8% in 2021, then soared 354.52% in 2023.
  • Precision Biosciences' Payables stood at $1.1 million in 2021, then plummeted by 42.92% to $653000.0 in 2022, then surged by 354.52% to $3.0 million in 2023, then crashed by 55.8% to $1.3 million in 2024, then rose by 2.13% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Payables are $1.3 million (Q3 2025), $1.1 million (Q2 2025), and $924000.0 (Q1 2025).